This inventor holds 25 USPTO granted patents and 24 published patent applications, plus 10 CIPO patents and 10 EPO patents, primarily in Pharmaceutical Formulations. Top assignees: Ascendis Pharma Growth Disorders A/s, Ascendis Pharma Bone Diseases A/s, Sanofi-A Ventis Deutschland Gmbh. Active years: 2014-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Heidelberg, DE (2014 - 2016)
- Mainz, DE (2020 - 2024)
Company Filing History:
11 out of 15 
8 out of 10 
4 out of 1,857 
Years Active: 2014-2026
Areas of Expertise:
Title: Felix Cleemann: Innovator in Controlled-Release Therapeutics
Introduction: Felix Cleemann, based in Mainz, Germany, is a prominent inventor in the field of pharmaceuticals, holding an impressive portfolio of 21 patents. His work primarily focuses on controlled-release therapeutic agents, contributing valuable advancements to medical science.
Latest Patents: Among his notable inventions, Cleemann has developed a groundbreaking patent for Controlled-release CNP agonists with low initial NPR-B activity. This inventive solution describes a controlled-release CNP agonist that releases its active components with a half-life of at least 6 hours under physiological conditions. Remarkably, this controlled-release formulation demonstrates a higher biological efficacy, with an EC that is at least 20-fold greater than that of the corresponding free CNP agonist, while the released CNP agonist has an EC that is at most 3-fold higher. In addition, he has patented PTH prodrugs, which encompass pharmaceutical compositions featuring these prodrugs and their therapeutic applications.
Career Highlights: Felix Cleemann has made significant contributions during his tenure at major pharmaceutical companies, including Ascendis Pharma Growth Disorders and Ascendis Pharma Bone Diseases. His innovative mindset has propelled his career forward, allowing him to claim multiple patents reflecting his expertise in drug development.
Collaborations: Throughout his career, Cleemann has collaborated with esteemed colleagues, including Harald Rau and Ulrich Hersel. Their joint efforts in pharmaceutical research have led to advancements in therapeutic solutions and increased the impact of their work in the field.
Conclusion: With a remarkable track record of 21 patents and a focus on pharmaceutical innovations, Felix Cleemann stands out as a key contributor in controlled-release therapeutics. His groundbreaking inventions and collaborations continue to influence the landscape of medicinal science, promising improved treatment options for various health conditions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile